Revelation Biosciences, Inc.
REVB
$1.46
-$0.04-2.67%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.64% | 1.39% | 4.36% | -9.28% | -14.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.14% | -2.43% | 10.14% | -24.59% | -35.32% |
| Operating Income | -8.14% | 2.43% | -10.14% | 24.59% | 35.32% |
| Income Before Tax | 14.92% | 70.86% | 23.51% | 21.66% | 14.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.92% | 70.86% | 23.51% | 21.66% | 14.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.92% | 70.86% | 23.51% | 21.66% | 14.72% |
| EBIT | -8.14% | 2.43% | -10.14% | 24.59% | 35.32% |
| EBITDA | -8.20% | 2.43% | -10.12% | 24.70% | 35.43% |
| EPS Basic | 95.60% | -- | -- | -- | -- |
| Normalized Basic EPS | 98.20% | -- | -- | -- | -- |
| EPS Diluted | 95.60% | -- | -- | -- | -- |
| Normalized Diluted EPS | 98.20% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 4,622.86% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 4,622.86% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |